Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...

as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of ...

Pharma’s return on research and development investment has risen sharply, with GLP-1 therapies for obesity and diabetes ...

Gallagher Re, a reinsurance brokerage and risk management services provider, has released a report on the impact of GLP-1 ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Popular diabetes and weight-loss drugs known as GLP-1s are helping to boost the biopharma sector's return on investment this ...